Fresenius Kabi Oncology trades higher on the BSE

27 Feb 2013 Evaluate

Fresenius Kabi Oncology is currently trading at Rs 116.00, up by 0.95 points or 0.83% from its previous closing of Rs. 115.05 on the BSE.

The scrip opened at Rs. 114.10 and has touched a high and low of Rs. 116.90 and Rs. 112.50 respectively. So far 29757 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 176.00 on 17-Apr-2012 and a 52 week low of Rs. 78.50 on 18-Oct-2012.

Last one week high and low of the scrip stood at Rs. 127.40 and Rs. 114.35 respectively. The current market cap of the company is Rs. 1827.53 crore.

The promoters holding in the company stood at 81.00% while Institutions and Non-Institutions held 9.29% and 9.71% respectively.

Fresenius Kabi Oncology has immediately taken steps to implement remedial measures at company’s API plant located at Kalyani, Nadia district in West Bengal and has voluntarily put the production on hold. The company’s dosage form plants in Himachal Pradesh continue normal production.

The company has taken this step after a recent routine USFDA inspection at the said plant whereby USFDA made certain observations relating to GMP non-conformities in respect of manufacturing, documentation practices and product testing. However, all finished products conform to approved standards and specifications.

Dabur Pharma, a leading company for cancer research and oncology drugs, was renamed  Fresenius Kabi Oncology after its acquisition by Fresenius Kabi, the leader in infusion therapy and clinical nutrition in Europe, Latin America, Asia Pacific as well as in the US, where it is a leading supplier of IV generic drugs.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×